After implementing a multifaceted physician-directed quality improvement (QI) initiative, an increased disparity in lowdensity lipoprotein (LDL) cholesterol control between white and black diabetes patients was observed. To examine possible causes, a retrospective analysis of 962 black and white patients treated continuously between 2008 and 2010 was performed. At baseline, 55.0% of whites and 49.8% of blacks were controlled (5.2% disparity). The disparity increased, with 61.8% of whites and 44.6% of blacks having control in 2010 (17.2% disparity). Among patients uncontrolled at baseline, blacks were less likely to become controlled. Among patients controlled at baseline, blacks were less likely to remain controlled; accounting for patient characteristics and changes in lipid-lowering drug prescription regimens did not attenuate these relationships. Physician-facing, general QI interventions may be insufficient to produce equity in LDL cholesterol control. Helping patients maintain prior success controlling cholesterol appears as important in addressing this disparity as is helping uncontrolled patients achieve control.
Health information technology (HIT) and performance measurement are increasingly used to drive quality improvement (QI). Previous studies have shown that interventions such as measurement and feedback of performance to providers, point-of-care clinical decision support, and the use of registries can improve overall quality of care but that general, practice-level QI interventions do not clearly lead to reduced racial disparities in quality. [1] [2] [3] [4] [5] [6] Understanding how generalized QI interventions influence racial disparities in quality may lead to more effective strategies to reduce disparities.
The UPQUAL (Using Precision Performance Measurement to Conduct Focused Quality Improvement) project was an example of an HIT-supported practice-wide QI initiative. It was implemented in February 2008 in the Northwestern Medical Faculty Foundation General Internal Medicine practice. 7 The intervention sought to improve performance on multiple chronic disease and preventive care quality measures simultaneously using rigorous performance measurement from electronic health record (EHR) data, physician-directed point-of-care computerized clinical decision support, and audit and feedback of performance data to primary care providers.
A previous study on the impact of UPQUAL observed racial disparities prior to implementing these QI methods. 1 Some disparities persisted even as overall quality improved. Of 7 performance measures for which baseline racial disparities were present prior to the start of this intervention in 2008, disparities declined for only 2 measures, remained stable for 4, and increased for 1 measure-control of low-density lipoprotein (LDL) cholesterol in diabetic patients. 1 These results illustrate the need to examine whether this QI intervention may have affected patients from different racial groups in different ways. The authors sought to perform an in-depth study of how LDL cholesterol control status and treatment plans differed by race before and during this QI intervention in order to better understand the causes of this increasing racial disparity in LDL cholesterol control.
Methods

Study Population
The study was conducted at the Northwestern Medical Faculty Foundation General Internal Medicine practice, a large primary care practice in an urban setting affiliated with an academic medical center. Northwestern University's institutional review board approved the study. The study population included all patients aged 18 to 89 with diabetes mellitus (based on a diagnosis code for diabetes mellitus on their past medical history or problem list) diagnosed before the start of the study period (prior to February 1, 2008) year. This measure is similar to the National Committee for Quality Assurance's Healthcare Effectiveness Data and Information Set measure. 9 Patients who did not meet the measure either had their last LDL cholesterol level ≥100 mg/dL or did not have an LDL cholesterol test done in the preceding 1 year.
Lipid-Lowering Drug Regimens. Lipid-lowering drugs (LLDs) included HMG-CoA reductase inhibitors ("statins"), bile acid sequestrants, niacin, ezetimibe, and fibrates. The LLD regimen at baseline and follow-up was defined as the drug or drugs that were active on the patient's EHR medication list on the date 6 weeks prior to the date of the LDL cholesterol test used to determine LDL control status for that date. These criteria were chosen because the authors sought to determine LLD regimens that were prescribed at the time the patients' LDL cholesterol levels were measured. When there was no LDL cholesterol value measured in the preceding year, the active medication list on February 1, 2008, or February 1, 2010, was used to indicate the LLD regimen for baseline and follow-up, respectively. High-potency statins were defined as atorvastatin ≥40 mg or rosuvastatin ≥20 mg, based on the ability of the daily doses of these medications to reduce LDL cholesterol >50%, and all others were defined as lower potency statins. 10, 11 Combination LLD therapies were defined as being prescribed both a statin and a nonstatin concurrently. Patients were considered to have had an increase in LLD regimen between 2008 and 2010 if any LLD was added (or substituted) or the dose of a previously prescribed LLD was increased. Decreases in regimen from 2008 to 2010 were defined as removal of any LLD or a decrease in the daily dosage of an LLD.
Statistical Analyses
Descriptive statistics (χ 2 for categorical variables and Student's t test for normally distributed continuous variables) were used to compare baseline patient characteristics of white and black patients.
First, univariable logistic regression was used to assess the unadjusted association between race and baseline LDL control. Then multivariable logistic regressions were performed with a model that included patient characteristics (sex, age, neighborhood education, ischemic vascular disease, Dartmouth Atlas comorbidity count, number of primary care visits in prior year, and insurance status). The third model added the presence of an LLD on the medication list at baseline.
Three regression models were performed to assess the relationship between race and achieving LDL control at follow-up, stratified by baseline LDL cholesterol control: (a) black race as the only independent variable, (b) after adding variables to indicate lack of baseline LLD prescription and changes in LLD treatment regimens, and (c) adding sex, age, neighborhood education, ischemic vascular disease, Dartmouth Atlas comorbidity count, number of primary care visits in prior year, and insurance status to the second model. Analyses were performed using STATA, version 12.1 (StataCorp, College Station, TX).
Chart Review for Patient Adherence
Retrospective review of EHR charts was performed for patients whose LDL cholesterol was not controlled in 2010 to identify physician-documented reasons why patients may have remained uncontrolled or fallen out of control. Physician-documented nonadherence to an LLD was defined as any mention in the chart of the patient not taking a prescribed LLD for any reason other than under the direction of a health care professional. Different kinds of physician-documented reasons for nonadherence were classified into a priori categories: the patient experienced an adverse drug event, had a financial barrier to accessing medication, perceived the risk of taking medication to be too great, or the patient preferred to not use medications in general. More than 1 reason for nonadherence could be present for each patient. One investigator (RZ) reviewed all internal medicine, endocrinology, and cardiology outpatient visit and telephone call notes from February 1, 2008, to February 1, 2010. A second investigator (SP) reviewed a subset of 10 random records. Adjudication of any nonadherence was in complete agreement with the first reviewer. There was a single discrepancy in categorization of nonadherence type.
Results
Baseline Characteristics and LDL Control
There were 962 patients who met inclusion criteria for this study, 56% of whom were white and 44% were black. Table 1 presents baseline patient characteristics by race. Black patients were more likely than white patients to be female, were less likely to be diagnosed with ischemic vascular disease, and made more general internal medicine visits in the prior year. Black patients were more likely than white patients to have Medicaid insurance and were less likely to have commercial insurance. Most patients (79.4%) had their LDL tested in the past year. The mean of the most recent LDL cholesterol levels among patients tested in the prior 1 year was significantly higher for black patients than white patients. Neighborhood socioeconomic characteristics, measured by the proportion of individuals in the neighborhood with an education reported as high school or less and by neighborhood median income, did not differ significantly between black and white patients. Black patients were less likely to have any LLD on their medication list at baseline and were less likely to be prescribed combination LLD therapy. Table 2 presents prescribed lipid-lowering regimens by race.
In 2008, 55.0% of white patients and 49.8% of black patients had controlled LDL cholesterol, a 5.1% difference between groups that was not statistically significant; univariable odds ratio (OR) for LDL control for black patients compared to white patients 0.81 (95% confidence interval [CI] = 0.63-1.04). This relationship was attenuated by adding patient characteristics to the model (adjusted OR = 0.88; 95% CI = 0.67-1.17) and baseline LLD prescription (adjusted OR = 0.94; 95% CI = 0.70-1.26). (Data not shown.)
Changes in LDL Cholesterol Control and Racial Disparity, 2008 to 2010
The racial disparity in LDL cholesterol control increased following the implementation of the multimodality QI intervention. As of February 1, 2010, 61.8% of whites and 44.6% of blacks met this measure, a 17.2% difference between groups and a 12.1% increase in the racial disparity between 2008 and 2010. Most of the cohort had an LDL test during the year prior to February 1, 2010, and this did not differ significantly by race (75.7% of white patients and 72.4% of black patients, P = .25). Among patients with controlled LDL cholesterol at baseline, 73.3% of white patients and 56.4% of black patients remained controlled (P < .001). Among patients with uncontrolled LDL cholesterol at baseline, 47.9% of white patients and 32.9% of black patients became controlled (P = .001).
Black patients were significantly less likely than white patients to have any LLD regimen on their active medication list in both 2008 and 2010 (P < .001 for both comparisons), but there was no appreciable change in the proportion of each group treated with an LLD during the study period (Table 2) . For patients on an LLD regimen, regimens differed significantly by race in both 2008 (P = .028) and 2010 (P = .017).
During the 2-year intervention period, a majority of uncontrolled patients had no change in their LLD regimens (Table 3) . Patients who were uncontrolled at baseline were significantly more likely to have their LLD regimen changed than patients controlled at baseline (38.5% of uncontrolled patients, 30.8% of controlled patients, P = .012). There was no statistically significant difference in types of changes during the 2-year period in LLD regimens between white and black patients for either the controlled or uncontrolled at baseline groups. Table 4 presents results for models of LDL cholesterol control in 2010 stratified by control status in 2008. In the unadjusted models, black race was associated with lower odds of having LDL control in 2010 for patients uncontrolled and controlled in 2008. Adjusting for lack of baseline LLD prescription and treatment changes (Model B) and adding patient demographic and clinical characteristics (Model C) did not attenuate the effect of race. Not having any LLD drug on the medication list was significantly associated with subsequent lack of control for both controlled and uncontrolled patients at baseline. Having the regimen decreased by 2010 was significantly associated with subsequent lack of control for patients who were controlled at baseline. 
Reasons for Not Achieving or for Losing LDL Cholesterol Control
Among patients with uncontrolled LDL cholesterol in 2010, structured chart review demonstrated that 40% of black patients and 29% of white patients had physiciandocumented nonadherence to LLD (P = .019). The reasons for nonadherence were not significantly different between black and white patients ( Table 5 ). The most commonly documented reasons for nonadherence were patient-experienced adverse drug events and patient preference to not use medication. Less commonly documented reasons included financial barriers and perceived risks of taking medication.
Discussion
This study sought to examine why the racial disparity in LDL cholesterol control among adults with diabetes cared for in the same care setting increased during a period of active QI. In a continuously followed cohort, performance for this measure improved by 6.8% for white patients and declined by 5.2% for black patients. Black patients were less likely to have an LLD on their medication list at both time points, and this difference did not change appreciably. Accounting for differences in patient characteristics and in drug treatments prescribed did not alter the observed racial difference in LDL cholesterol control. Black patients were more likely than white patients to remain uncontrolled (among those uncontrolled at baseline) and to become uncontrolled (among those controlled at baseline).
Other studies addressing racial differences in LDL cholesterol control in diabetes have shown varying patterns of change during times of general QI. One study conducted in the Veterans Affairs health care system and another in an integrated health care system in Michigan showed that during periods of considerable QI, racial differences in LDL control in diabetes were not reduced. 12, 13 Another study from an integrated health care system in Massachusetts showed a slight reduction in the blackwhite disparity; however, this was done at a time when baseline levels of LDL cholesterol testing and LDL control were low (1997) (1998) (1999) (2000) (2001) and the amount of change in the racial disparity was small (2.5% reduction). 3 General QI interventions directed at patients (eg, individualized case management programs using teams) may be among the more potent interventions to improve control of chronic conditions. 14 This approach has led to similar improvement in disease control for diabetes across different racial groups. 15 This study examined whether changes in drug prescribing, which may have occurred in response to the QI efforts, differed by race and could potentially account for the increasing disparity. White patients were more likely than black patients to be prescribed any LLD drug regimen in 2008 (80% vs 70%), and this factor seemed to have a small influence on the relationship between race and LDL control in 2008. However, this difference did not change by 2010 (79% vs 69%), and accounting for intensification or reduction in LLD regimens did not attenuate the relationships between LDL control and race in 2010. Therefore, evidence was not found to support the notion that differences in prescribed LLD treatments over time (as represented by the medication list in the EHR) caused the racial disparity to increase. There are limitations to the medication data available through EHRs that must be kept in mind when interpreting these data. Although treatment intensification is associated with subsequent LDL control, 16 it is unknown how often a lack treatment intensification in response to uncontrolled LDL cholesterol is related to providers' inaction and how much is driven by patients' actions or preferences. Reliable information on adherence to medications listed in the EHR also is lacking, so the extent to which nonadherence contributes to the observed findings is unable to be determined. The chart review revealed that physicians commonly documented patient nonadherence to prescribed LLD regimens (40% of black patients, 29% of white patients), suggesting that patient behaviors, preferences, and ability to tolerate medication are major determinants of whether prescribed LLDs are used. QI interventions should be tested that not only focus on providers' prescribing actions but also monitor and support patient medication usage behaviors and proactively identify and address ameliorable adverse drug events when they occur.
A large part of the increase in the racial disparity observed was related to a disproportionally large number of black patients with previously controlled LDL cholesterol who did not remain controlled during follow-up. Point-of-care clinical decision support that calls attention to patients who were not currently meeting the quality measure, such as was used here, does not do anything to encourage physicians to assess patients' current medication use, proactively detect medication discontinuation, and formulate new care plans before a patient returns for periodic laboratory monitoring that shows inadequate risk factor control. System-level interventions to promote long-term persistence with important medical therapies among both patients who are and are not currently meeting quality of care goals should be tested. The incorporation of pharmacy data into clinics' information systems for the purposes of identifying when patients stop refilling medications and triggering prompt action holds promise as a way to address the quality challenge observed in this study. 17, 18 These findings should be viewed in the context of several additional limitations. The study was conducted at one site and the findings may not be generalizable to other settings. Prescription drug data from EHRs were used, which may be a better reflection of clinician action than pharmacy claims data, but these data cannot show which patients filled prescriptions. Socioeconomic differences were measured using geospatial coding to neighborhood characteristics. Had patient-specific data been available, it may have been found that more of the observed differences were mediated by socioeconomic differences. The size of the patient population available for study was 962 patients; therefore, some estimates are imprecise. Chart reviews are a very limited way to obtain information about patients' medication use. Standardized patient interviews may provide more reliable measures of patient behaviors and attitudes pertaining to medications.
Ultimately, in a fixed cohort of black and white patients with diabetes receiving care from the same group of providers, taking into consideration clinical and demographic characteristics and changes in prescribed LLD regimens, the authors were unable to account for the increasing racial disparity in LDL control that occurred during a 2-year period of active QI. This finding does not support the notion that general QI initiatives that rely on provider-directed interventions like clinical decision support and audit and feedback will improve equity by race in the control of intermediate clinical outcomes.
